Skip to content
Peptide research

Survodutide

Also known as BI 456906
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

Survodutide is a dual glucagon/GLP-1 receptor agonist marketed for weight loss, blood sugar control, and liver fat reduction in MASH. Evidence is human and fairly strong, though cardiovascular benefit is speculative. The main concern is tolerability: nausea and vomiting occur several times more than placebo, driving high discontinuation; long-term cardiovascular safety is unproven. It is not FDA-approved, so supply falls outside standard channels.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Significant Weight Loss

    High

    Phase 2 human trial showed about 14.9% weight loss at the highest dose versus 2.8% placebo.

  • Glycemic Control

    High

    16-week human RCT in type 2 diabetes showed dose-dependent HbA1c reductions versus placebo.

  • MASH/Liver Fat Reduction

    High

    48-week biopsy-confirmed human RCT showed MASH improvement in 62% of patients versus 14% placebo.

Evidence limits

Evidence Level
Phase 3

Survodutide has completed multiple Phase 1 and Phase 2 trials with approximately 956 participants across four key RCTs (Roux 2024 n=384, Bluher 2023 n=411, Jungnik 2022 n=125, Yazawa 2023 n=36). Phase 3 development includes the SYNCHRONIZE obesity program and the LIVERAGE MASH program. Results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD have been published. All Phase 2 trials demonstrated statistically significant efficacy for weight loss and metabolic improvement with an acceptable safety profile dominated by GI side effects.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of MTC

    Absolute

    Dual GLP-1/glucagon agonist carries thyroid C-cell tumor risk.

  • History of pancreatitis

    High

    GLP-1 class effect on pancreatitis risk. Monitor closely.

  • Severe gastroparesis

    High

    GLP-1 component slows gastric emptying.

General cautions

  • Pregnancy

    Absolute

    Investigational — no safety data.

Risk summary(10)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Gastrointestinal adverse events: nausea (3.3x placebo risk), vomiting (6.64x), diarrhea (1.89x), dyspepsia (6.93x), early satiety (6.44x)

    High
  • Higher treatment discontinuation rate due to adverse events (RR 4.53 vs placebo)

    High
  • Mild increase in heart rate (mean 2.7 bpm increase vs 0.1 bpm for placebo)

    Moderate
  • Dose-dependent GI tolerability — higher doses may cause more pronounced nausea and vomiting

    High
  • Long-term cardiovascular safety not yet established (the SYNCHRONIZE-CVOT trial, NCT06077864, completed in June 2026; no outcome results in the cited literature)

    Moderate
  • Potential for hypoglycemia when combined with insulin or sulfonylureas (theoretical risk based on GLP-1R agonist class)

    Moderate
  • Published phase 3 obesity data extend to 76 weeks; longer-term safety remains under study.

    Moderate
  • Injection site reactions possible with subcutaneous administration

    Low
  • Weight regain upon discontinuation not yet characterized

    Moderate
  • Safety in patients with severe renal or hepatic impairment not fully established

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.